Clinical Trial

A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-29.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06716619
Lead Sponsor Guangzhou FineImmune Biotechnology Co., LTD.
Collaborators: Sun Yat-sen University
Conditions Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
Enrollment 32 participants
Start Date 2025-02-13
Primary Completion 2026-12-19 (estimated)
Study Completion 2027-12-19 (estimated)
Updated on ClinicalTrials.gov 2025-03-26